Results 131 to 140 of about 790,096 (261)
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product
Ophthalmology and TherapyIntroduction ABP 938 is being developed as a biosimilar to Eylea® (aflibercept reference product [RP]), an anti-vascular endothelial growth factor (VEGF) drug used in the management of retinal diseases.
Neungseon Seo +5 more
doaj +1 more source
AboutOpenBackground: The availability of high-efficacy disease-modifying therapy (DMT), including natalizumab, improved treatment efficacy in adults with highly-active relapsing-remitting multiple sclerosis (RRMS). Natalizumab patent protection has expired, and the natalizumab biosimilar (Tyruko®) has been recently reimbursed by AIFA.
Roberto Bergamaschi +2 more
openaire +2 more sources
Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review [PDF]
Grace E Fox,1 Mark Bernauer,1 Jennifer M Stephens,1 Bianca Jackson,1 Joshua A Roth,2 Ahmed Shelbaya2,3 1Strategic Market Access, OPEN Health, Bethesda, MD, USA; 2Global Access and Value, Pfizer Inc., New York, NY, USA; 3Department of Epidemiology ...
Stephens JM +5 more
core
Global Competitiveness in Pharmaceuticals: A European Perspective [PDF]
The report examines the competitive position of the European pharmaceutical companies and industries, and compares them with the pharmaceutical companies and industries in other parts of the world, particularly the US.
Gambardella, Alfonso +2 more
core
Global Competitiveness in Pharmaceuticals: A European Perspective [PDF]
, 2000 The report examines the competitive position of the European pharmaceutical companies and industries, and compares them with the pharmaceutical companies and industries in other parts of the world, particularly the US.
Gambardella, Alfonso +2 more
core
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
, 2017 Maria Victoria Borrás Pérez,1 Berit Kriström,2 Tomasz Romer,3 Mieczyslaw Walczak,4 Nadja Höbel,5 Markus Zabransky5 1Hospital General de Granollers, Granollers, Barcelona, Spain; 2Department of Clinical Sciences, Pediatrics, Ume ...
Zabransky M +5 more
core
Journal of Health Policy & Outcomes Research, 2013 Objectives: Due to the increased number in biosimilar drugs getting marketing authorization, there is a question to be answered which reimbursement procedure should be followed. Methods: The TPPC task force has checked the approach to biosimilar drugs by WHO, at the EMA level and in a few countries worldwide.
openaire +1 more source
Rheumatology and TherapyIntroduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS).
Ran Jin +8 more
doaj +1 more source
A practical guide about biosimilar data for health care providers treating inflammatory diseases
, 2017 Joseph Markenson,1,2 Daniel F Alvarez,3 Ira Jacobs,4 Carol Kirchhoff5 1Department of Rheumatology, 2Department of Medicine, Hospital for Special Surgery, New York, NY, 3Pfizer Inc, Collegeville, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc ...
Jacobs I +3 more
core